Dr Konstantinos Tzelepis will join Cambridge Stem Cell Institute as a Principal Investigator, with research focusing on RNA modifications in stem cell homeostasis.
Dr Tzelepis will be moving from The Milner Therapeutics Institute, where he also served as a PI. Prior to his appointment at Milner, he was a Wellcome Trust Sir Henry Wellcome Fellow at Harvard University and the University of Cambridge.
On joining CSCI, Dr Tzelepis says:
"I am very pleased that my group is joining the Cambridge Stem Cell Institute, which is one of the best places globally to study stem cell biology. We are now planning to make full use of the institute's academic excellence and expand our mechanistic and translational investigations in order to dissect the role of RNA and its modifications in the biology of various tissue stem cells."
Beginning in May, Dr Tzelepis and his group will join the team of 28 other Principal Investigators (also known as Group Leaders) in fulfilling CSCI's mission to transform human health through a deep understanding of stem cell biology.
Director of CSCI Bertie Göttgens comments:
"We are delighted to have Kostas join the CSCI as a new group leader. Kostas has pioneered research into the biological relevance of post-transcriptional modifications of RNA, which I believe will have broad impact across many areas of stem cell function in health and disease."
Dr Tzelepis' recent research can be found in the publications listed below.
Publications
- Yankova, Blackaby et al. Small molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature 2021
- Orellana et al. METTL1-mediated m7G modification of Arg-TCT tRNA drives oncogenic transformation. Molecular Cell 2021
- Mikutis et al. meCLICK-Seq – a substrate-hijacking and RNA degradation strategy for the study of RNA methylation. ACS Central Science 2020